Results 61 to 70 of about 15,728 (206)
Атеротромбоз, 2018 Prasugrel is a third-generation thienopyridine that provides earlier onset of action, has a reduced probability of insensitivity to the drug, a greater degree of inhibition of ADP-induced platelet aggregation compared to clopidogrel.
O. O. Shakhmatova, A. L. Komarov
doaj +1 more source
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus.
JACC: Cardiovascular Interventions, 2020 OBJECTIVES The aim of this study was to assess the efficacy and safety of ticagrelor versus prasugrel in patients with diabetes mellitus (DM) presenting with acute coronary syndromes (ACS) in whom invasive therapy was planned.
G. Ndrepepa +17 more
semanticscholar +1 more source
Cardiovascular Intervention and Therapeutics, 2021 The recommended maintenance dose of prasugrel for East Asian populations (i.e., Japanese and Taiwanese) is 3.75 mg as part of dual antiplatelet therapy (DAPT) for the prevention of recurrent ischemia and stent thrombosis in acute coronary syndrome (ACS).
Ping-Yen Liu +17 more
semanticscholar +1 more source
Journal of Diabetes Investigation, EarlyView.Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi +4 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 Background Few studies have examined how antiplatelet therapies are selected during the routine care of acute myocardial infarction patients, particularly relative to the patient's estimated mortality and bleeding risks.
Amit N. Vora +10 more
doaj +1 more source
Clinical Cardiology, 2021 Clopidogrel, prasugrel and ticagrelor, acting on platelet P2Y12 receptor, are commonly used for prevention of stent thrombosis (ST) among patients who underwent percutaneous coronary intervention (PCI).
Wenwen Chen +7 more
semanticscholar +1 more source
Health Technology Assessment, 2015 Background: Acute coronary syndromes (ACSs) are life-threatening conditions associated with acute myocardial ischaemia. There are three main types of ACS: ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (
Janette Greenhalgh +9 more
doaj +1 more source
Safety of Prasugrel in Indian patients – Multicentric registry of 1000 cases
Indian Heart Journal, 2014 Background: Clopidogrel has been the only available antiplatelet drug used along with aspirin in patients of ACS. In recent years 2 new antiplatelet drugs (Prasugrel and Ticagrelor) have become available.
Upendra Kaul +14 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 BackgroundThis meta-analysis mainly aimed to compare the impact of prasugrel and ticagrelor on platelet reactivity (PR) in patients with acute coronary syndrome (ACS).MethodsWe searched four electronic databases to identify randomized controlled trials ...
Lulu Dai +3 more
doaj +1 more source
JACC: Cardiovascular Interventions, 2021 OBJECTIVES This study sought to compare the pharmacodynamic effects of pre-hospitally administered P2Y12 inhibitor prasugrel in crushed versus integral tablet formulation in patients with ST-segment elevation myocardial infarction (STEMI) undergoing ...
R. Vogel +16 more
semanticscholar +1 more source